Featured Research

from universities, journals, and other organizations

Monoclonal antibodies: Short-term therapy for long-term treatment of chronic viral infections?

Date:
June 12, 2010
Source:
CNRS (Délégation Paris Michel-Ange)
Summary:
Monoclonal antibodies are the largest class of biotherapeutic drugs. When administered to infected organisms to blunt the propagation of pathogenic viruses, they may also induce a long-lasting and protective antiviral immune response similar to that achieved by vaccination. These results raise hopes for the treatment of certain severe and chronic viral infections.

Monoclonal antibodies are the largest class of biotherapeutic drugs. When administered to infected organisms to blunt the propagation of pathogenic viruses, they may also induce a long-lasting and protective antiviral immune response similar to that achieved by vaccination.

These results obtained in mice by the "Oncogenèse et Immunothérapie" group at the Institut de Génétique Moléculaire de Montpellier (CNRS/Universités Montpellier 1 and 2), have been published on 10 June in PLoS Pathogens. They raise hopes for the treatment of certain severe and chronic viral infections.

Antibodies (AB) are molecules that are produced by the immune system to defend itself against cancer cells and infective agents. Of these, monoclonal antibodies1 can be developed and produced at a large scale to treat a variety of diseases: cancer, inflammatory or infectious diseases, etc. They thus constitute the largest class of biotherapeutic drugs to date and are being considered with increasing interest for the treatment of severe and chronic viral infections such as HIV (Human Immunodeficiency Virus) or HCV (Hepatitis C Virus), against which current therapies are still insufficient.

Until now, the only mechanism of action of antiviral monoclonal antibodies that was really considered by the medical and scientific communities was the neutralization and direct elimination of viruses in infected organisms.

Using a model of viral leukemia in mice, the "Oncogenèse et Immunothérapie" group at the Institut de Génétique Moléculaire in Montpellier (CNRS/Universités Montpellier 1 and 2), headed by Marc Piechaczyk, has recently shown that under certain conditions, a very short course of treatment (a few days) with antiviral monoclonal antibodies can have an additional effect similar to that of a vaccine. After three weeks, and even though the injected monoclonal antibodies had disappeared, the researchers indeed detected a potent and long-lasting (more than a year) antiviral immune response that was sufficient for the mice to avoid death from leukemia.

The team identified an unexpected mechanism enabling the monoclonal antibodies to induce protective antiviral immunity. This mechanism is based on their ability to recognize not only circulating viral particles but also certain viral proteins expressed at the surface of infected cells. These new findings may help to trigger protective immunity. They should be borne in mind by the biologists who design and develop therapeutic antiviral monoclonal antibodies.

In mice, a short and early course of therapeutic monoclonal antibodies targeting both the viruses and the cells infected by these viruses thus enables permanent recovery from a fatal chronic infection. If this observation can be extrapolated to humans, it will result in a therapeutic benefit not only for patients but also for society, in that it will help to significantly reduce the cost of monoclonal antibody therapies, which remains prohibitive in most cases.

Note:

1. Monoclonal antibodies are entirely pure antibodies that only recognize one type of antigen. Because of their specificity, which can easily be established, they are increasingly being used for therapeutic purposes for the selective destruction of tumor or viral cells and to combat certain inflammatory disease such as rheumatoid arthritis.


Story Source:

The above story is based on materials provided by CNRS (Délégation Paris Michel-Ange). Note: Materials may be edited for content and length.


Journal Reference:

  1. Henri-Alexandre Michaud, Tiphanie Gomard, Laurent Gros, Kevin Thiolon, Roudaina Nasser, Chantal Jacquet, Javier Hernandez, Marc Piechaczyk, Mireia Pelegrin, Richard A. Koup. A Crucial Role for Infected-Cell/Antibody Immune Complexes in the Enhancement of Endogenous Antiviral Immunity by Short Passive Immunotherapy. PLoS Pathogens, 2010; 6 (6): e1000948 DOI: 10.1371/journal.ppat.1000948

Cite This Page:

CNRS (Délégation Paris Michel-Ange). "Monoclonal antibodies: Short-term therapy for long-term treatment of chronic viral infections?." ScienceDaily. ScienceDaily, 12 June 2010. <www.sciencedaily.com/releases/2010/06/100611124651.htm>.
CNRS (Délégation Paris Michel-Ange). (2010, June 12). Monoclonal antibodies: Short-term therapy for long-term treatment of chronic viral infections?. ScienceDaily. Retrieved April 19, 2014 from www.sciencedaily.com/releases/2010/06/100611124651.htm
CNRS (Délégation Paris Michel-Ange). "Monoclonal antibodies: Short-term therapy for long-term treatment of chronic viral infections?." ScienceDaily. www.sciencedaily.com/releases/2010/06/100611124651.htm (accessed April 19, 2014).

Share This



More Health & Medicine News

Saturday, April 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

'Holy Grail' Of Weight Loss? New Find Could Be It

'Holy Grail' Of Weight Loss? New Find Could Be It

Newsy (Apr. 18, 2014) — In a potential breakthrough for future obesity treatments, scientists have used MRI scans to pinpoint brown fat in a living adult for the first time. Video provided by Newsy
Powered by NewsLook.com
Little Progress Made In Fighting Food Poisoning, CDC Says

Little Progress Made In Fighting Food Poisoning, CDC Says

Newsy (Apr. 18, 2014) — A new report shows rates of two foodborne infections increased in the U.S. in recent years, while salmonella actually dropped 9 percent. Video provided by Newsy
Powered by NewsLook.com
Scientists Create Stem Cells From Adult Skin Cells

Scientists Create Stem Cells From Adult Skin Cells

Newsy (Apr. 17, 2014) — The breakthrough could mean a cure for some serious diseases and even the possibility of human cloning, but it's all still a way off. Video provided by Newsy
Powered by NewsLook.com
Obama: 8 Million Healthcare Signups

Obama: 8 Million Healthcare Signups

AP (Apr. 17, 2014) — President Barack Obama gave a briefing Thursday announcing 8 million people have signed up under the Affordable Care Act. He blasted continued Republican efforts to repeal the law. (April 17) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins